MJARF (MJardin Group) Cash Conversion Cycle: 71.15 (As of Sep. 2021)


What is MJardin Group Cash Conversion Cycle?

MJardin Group MJARF -99.00% Cash Conversion Cycle is 71.15 as of Sep. 2021.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

MJardin Group's Days Sales Outstanding for the three months ended in Sep. 2021 was 61.88.
MJardin Group's Days Inventory for the three months ended in Sep. 2021 was 216.74.
MJardin Group's Days Payable for the three months ended in Sep. 2021 was 207.47.
Therefore, MJardin Group's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2021 was 71.15.


MJardin Group  (OTCPK:MJARF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


MJardin Group Cash Conversion Cycle Related Terms


MJardin Group Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for MJardin Group's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MJardin Group Cash Conversion Cycle Chart

MJardin Group Annual Data
Trend Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17 Aug18 Dec19 Dec20
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -139.82 -178.03

MJardin Group Quarterly Data
Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.71 -58.66 77.04 154.80 71.15

MJARF vs EAPH, FPSUF, GCAN: Cash Conversion Cycle Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MJardin Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MJardin Group Cash Conversion Cycle vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MJardin Group's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where MJardin Group's Cash Conversion Cycle falls into.



MJardin Group Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

MJardin Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2020 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=50.27+213.8-442.1
=-178.03

MJardin Group's Cash Conversion Cycle for the quarter that ended in Sep. 2021 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=61.88+216.74-207.47
=71.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 71.15 mean?
MJardin Group (MJARF) has a Cash Conversion Cycle of 71.15 as of Sep. 2021. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on MJardin Group and its competitors.
Is MJardin Group's Cash Conversion Cycle too high?
MJardin Group's current Cash Conversion Cycle is 71.15. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. MJardin Group's value of 71.15 is 51.2% below this industry median.
How does MJardin Group's Cash Conversion Cycle compare to EAPH and FPSUF?
MJardin Group's Cash Conversion Cycle of 71.15 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. MJardin Group's value of 71.15 is 51.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MJardin Group's current Cash Conversion Cycle of 71.15 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on MJardin Group and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MJardin Group's current Cash Conversion Cycle is 71.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MJardin Group stock overvalued right now?
MJardin Group (MJARF) has a current Cash Conversion Cycle of 71.15. The current Cash Conversion Cycle is 71.15 and 51.2% below the Drug Manufacturers industry median of 145.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For MJardin Group (MJARF), the current Cash Conversion Cycle is 71.15 as of Sep. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MJardin Group Business Description

Address 1 Toronto Street, Suite 801, Toronto, ON, CAN, M5C 2V6
MJardin Group Inc is a Canada based cannabis cultivation and management company. It is engaged in the cultivation, processing, and distribution of medical cannabis. The company's operating segment includes Cultivation management in USA and Cultivation operations in Canada. It generates maximum revenue from the Cultivation management in USA segment. Cultivation management in USA segment engaged in the management services to owners of cultivation and dispensary facilities. The services provided are consulting, design, operational, and other management services.